Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans

Drug Metabolism and Disposition

Volumn 26, Issue 3, 1998, Pages 240-245

  Matsushima, Hiroshi ^a   Kamimura, Hidetaka ^b   Soeishi, Yoshiaki ^b   Watanabe, Takashi ^b   Higuchi, Saburo ^b   Tsunoo, Michio ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; TAMSULOSIN;

ADULT; ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; DOGS; HUMANS; INFANT; LIVER; MALE; MOLECULAR STRUCTURE; PROTEIN BINDING; RATS; SULFONAMIDES;

EID: 0031895694     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Aggeler PM, O'Reilly RA, Leong L and Kowitz PE (1967) Potentiation of anticoagulant effect of warfarin by phenylbutazone. N Engl J Med 276:496-501.
2. Dahlqvist R, Borgå O, Rane A, Walsh Z and Sjöqvist F (1979) Decreased plasma protein binding of phenytoin in patients on valproic acid. Br J Clin Pharmacol 8:547-552.
3. Dale O and Nilsen OG (1984) Differences in the serum protein binding of prazosin in man and ral. Biochem Pharmacol 33:1719-1724.
4. Dedrick RL, Zaharko DS and Lutz RJ (1973) Transport and binding of methotrexate in vivo. J Pharm Sci 62:882-890.
5. Evans GH, Nies AS and Shand DG (1973) The disposition of propranolol. III. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog, and rat. J Pharmacol Exp Ther 186:114-122.
6. Greenway CV and Stark RD (1971) Hepatic vascular bed. Physiol Rev 51:23-65.
7. Grossman SH, Davis D, Kitchell BB, Shand DG and Routledge A (1982) Diazepam and lidocaine plasma protein binding in renal disease. Clin Pharmacol Ther 31:350-357.
8. Honda K and Nakagawa C (1986) Alpha-1 adrenoceptor antagonistic effects of the optical isomers of YM-12617 in rabbit lower urinary tract and prostate. J Pharmacol Exp Ther 239:512-516.
9. 1-adrenoceptor antagonist and its individual optical enantiomers. Naunyn-Schmiedeberg's Arch Pharmacol 336:295-302.
10. 1A adrenoceptor antagonist tamsulosin in human: comparison with data from interspecies scaling. J Pharm Sci 86:1156-1161.
11. 1-acid glycoprotein and albumin. Clin Pharmacol Ther 32:295-302.
12. Kamimura H, Sasaki H and Kawamura S (1984) Pharmacokinetics of amosulalol, an α,β-adrenoceptor blocker, in rats, dogs and monkeys. Xenobiotica 14:613-620.
13. Kamimura H, Sasaki H and Kawamura S (1985) Metabolism of amosulalol hydrochloride in man: quantitative comparison with laboratory animals. Xenobiotica 15:413-420.
14. 1-acid glycoprotein in health and disease. Pharmacol Rev 40:1-47.
15. McElnay JC and D'Arcy PF (1980) Displacement of albumin-bound warfarin by antiinflammatory agents in vitro. J Pharm Pharmacol 32:709-711.
16. McNamara PJ, Lalka D and Gibali M (1981) Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med 98:730-740.
17. Nakashima N, Asano M, Ohguchi S, Hashimoto H, Seki T, Miyazaki M and Takenaka T (1984) Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses. Clin Pharmacol Ther 36:436-443.
18. Øie S (1979) Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 68:1203-1205.
19. Pang KS and Rowland M (1977) Hepatic clearance of drugs. I. theoretical considerations of a "Well-stirred" model and a "Parallel tube" model, influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653.
20. Sawada S, Hanano M, Sugiyama Y, Harashima H and Iga T (1984) Prediction of the volumes of distribution of basic drugs in humans based on data from animals. J Pharmacokinet Biopharm 12:587-596.
21. Sjöholm I, Kober A, Odar-Cederlöf I and Borgå O (1976) Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors. Biochem Pharmacol 25:1205-1213.
22. Soeishi Y, Matsushima H, Teraya Y, Watanabe T, Higuchi S and Kaniwa H (1996a) Metabolism of tamsulosin in rat and dog. Xenobiotica 26:355-365.
23. Soeishi Y, Matsushima H, Watanabe T, Higuchi S, Cornelissen K and Ward J (1996b) Absorption, metabolism and excretion of tamsulosin hydrochloride in man. Xenobiotica 26:637-645.
24. Wilkinson GR and Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
25. 1-adrenoceptor antagonist binding in human prostate and aorta. Clin Exp Pharmacol Physiol 21:405-411.